

# WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 13 janvier 2025 12:39

## LABORATORY INFORMATION

<b>*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:</b>	Lumpy skin disease
<b>*Address of laboratory:</b>	Groeselenberg 99, 1180 Uccle
<b>*Tel:</b>	+3223790627
<b>*E-mail address:</b>	nick.deregge@sciensano.be
<b>Website:</b>	<a href="https://www.sciensano.be/en">https://www.sciensano.be/en</a>
<b>*Name (including Title) of Head of Laboratory (Responsible Official):</b>	Prof. Nick De Regge
<b>*Name (including Title and Position) of WOAH Reference Expert:</b>	Prof. Nick De Regge; head of the service Exotic and vector-borne diseases
<b>*Which of the following defines your laboratory? Check all that apply:</b>	Governmental

## TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Direct diagnostic tests		Nationally	Internationally
real time PCR pan-capripox	Yes	5	50
real time PCR DIVA LSDV	No	0	50

## TOR2: REFERENCE MATERIAL

Nick De Regge - -

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA?H Member Countries	Country of recipients
LSDV inactivated virus	real time PCR	in BSL3 laboratory	0	5ml	2	CROATIA, UNITED KINGDOM,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

Name of the new test or diagnostic method developed	Description and References (Publication, website, etc.)
LSDV IGRA	manuscript under review

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

Yes

Name of the new vaccine developed	Description and References (Publication, website, etc)
Phivax LSDV	Neethling Strain-Based Homologous Live Attenuated LSDV Vaccines Provide Protection Against Infection with a Clade 2.5 Recombinant LSDV Strain Philips, W., Haegeman, A., Krešić, N., Mostin, L., De Regge, N Vaccines 2025, 13, 8. <a href="https://doi.org/10.3390/vaccines13010008">https://doi.org/10.3390/vaccines13010008</a>

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

Name of WOA?H Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
		pan-capripox PCR, LSDV		

Nick De Regge - -

PAKISTAN	2024-08-31	DIVA PCR, partial sequencing	5	0
NIGERIA	2024-01-31	pan-capripox PCR, LSDV DIVA PCR, partial sequencing, Whole genome sequencing	50	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

Name of the WOA Member Country receiving a technical consultancy	Purpose	How the advice was provided
LIBYA	support upon LSDV outbreak in Libia	online meeting

## TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOA?

Yes

Research need : 1

**Please type the Research need:** DIVA vaccine and diagnostics for LSDV

**Relevance for WOA** Disease Control, Standard Setting, Facilitation of international collaboration,

**Relevance for the Code or Manual** Code, Manual,

**Field** Epidemiology and Surveillance, Diagnostics, Vaccines,

**Animal Category** Terrestrial,

**Disease:**

Lumpy skin disease

**Kind of disease (Zoonosis, Transboundary diseases)** Transboundary diseases,

**If any, please specify relevance for Codes or Manual, chapter and title**

(e.g. Terrestrial Manual Chapter 2.3.5 - Minimum requirements for aseptic production in vaccine manufacture)

Answer:

**Notes:**

Answer:

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

Nick De Regge - -

If the answer is yes, please provide details of the data collected:

detection and characterization of LSDV strains present in Nigeria and Pakistan

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

only dissemination to involved countries

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

5

*epidemiological and technical information presented during multiple congresses (e.g. EuFMD open Session)*

c) National conferences:

d) Other (Provide website address or link to appropriate information):

3

*epidemiological and technical information presented during multiple virtual learning courses (e.g. FAO VLC for Asia, FAO VLC for North-Africa) and seminars for specific countries or regions (e.g. Libya, North-Africa upon LSDV outbreak)*

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

Yes

a) Technical visit : 0

b) Seminars : 3

c) Hands-on training courses: 1

Nick De Regge - -

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	NORTH MACEDONIA (REP. OF)	2
B	BANGLADESH	50
B	ALGERIA	150

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	see document last year	
ISO17043	see document last year	

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
LSDV pan-capripox PCR, LSDV isolation, LSDV ELISA	BELAC, ISO17025, ISO17043

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Contained use approval for work with capripox viruses under BSL3 conditions from the 'Leefmilieu Brussel'

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

Yes

Title of event	Date	location	Role (speaker, presenting poster, short communications)	Title of the work presented
GF-TAD SGE LSDV	2024-02-29	online	speaker	LSDV epidemiology in Asia and work of the EURL
WOAH regional seminar for national focal points South-East Asia	2024-07-16	online	speaker	LSDV epidemiology and diagnosis
WOAH 5th coordination meeting for SEA	2024-12-11	online	speaker	Brief update on LSDV epidemiology, diagnostics, transmission and vaccines

## TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/participant)	No. participating Laboratories	Participating WOAHP Ref. Labs/organising WOAHP Ref Lab
LSDV serology and virology	organiser	55	WOAHP RL LSDV Pirbright

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons <sup>1</sup>	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
LSDV serology and virology	organiser (as EURL for capripox viruses)	45	LSDV ELISA, LSDV VNT, LSDV IPMA, LSDV PCRs	DENMARK,
LSDV virology	organiser (as EURL for capripox viruses)	1	LSDV PCRs	GREECE,
LSDV virology and serology	organiser (as WOAHP RL)	6	LSDV ELISA, LSDV VNT, LSDV IPMA, LSDV PCRs	INDONESIA, THAILAND, VIETNAM,

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

Yes

Kind of consultancy	Location	Subject (facultative)
review ASEAN LSDV control program	online	LSDV

**Nick De Regge - -**

review TOR ASEAN LSDV control program	online	LSDV
WOAH expert group to revise the LSDV code chapter (supplementary to the drafting of the SPPV code chapter)	Paris	LSDV

29. Additional comments regarding your report:

No